Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 26
---
effected a ratio change to the Depositary Shares, pursuant to which the ratio of Ordinary Shares to Depositary Shares was changed such
that one Depositary Share represented 10,000 Ordinary Shares. Our Ordinary Shares were not affected by this change and no fractional
Depositary Shares were issued.

On November 22, 2024,
we held the November GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares of £0.001
nominal value each into one Ordinary Share of £0.00005 nominal value and 19 C Deferred Shares of £0.00005 nominal value each.

On January 17, 2025, we entered into a securities purchase agreement, or ELOC, with newly formed C/M Capital Master Fund LP, or C/M, pursuant to which we, subject to the restrictions and satisfaction of the conditions in the ELOC, have the right, but not the obligation, to sell toC/M, andC/M is obligated to purchase, up to $35.0 million of newly issued Depositary Shares over a 36-month period, unless the ELOC is terminated in accordance with its terms. As of June 30, 2025, we have sold 51,468,000,000 Ordinary Shares under the ELOC, for gross proceeds of approximately $8.6 million, andissued 1,794,060,000 Ordinary Shares to C/M in satisfaction of a commitment fee.

On May 15, 2025, we entered
into the 2025 Warrant Agreements with certain holders of our outstanding Series E Warrants, Series H Warrants, Series J Warrants, and
Series K Warrants issued in prior transactions, pursuant to which the holders agreed to exercise certain of such warrants in exchange
for a reduction in exercise price of each warrant to $3.10 per share. An aggregate of 20,041 warrants were exercised for aggregate gross
proceeds of approximately $62,000, before estimate offering expenses.

Since their respective
dates of issuance, we have issued 1,529,030,000 Ordinary Shares upon exercises of the Series H Warrants, Series J Warrants and Series
K Warrants, including warrants exercised pursuant to the terms of the 2025 Warrant Agreements (other than shares held in abeyance).

On June 11, 2025, we held
the June 2025 GM and our shareholders passed resolutions to, among other things, subdivide our Ordinary Shares